AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 26999510 — intervention group
Group type: EXPERIMENTAL
Intervention: Levocetirizine 5 mg
Number of subjects: 0
Study 26999510 — intervention group
Group type: EXPERIMENTAL
Intervention: Fexofenadine 60 mg
Number of subjects: 0
Study 26999510 — intervention group
Group type: EXPERIMENTAL
Intervention: Diphenhydramine 50 mg
Number of subjects: 0
Study 26999510 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 24282157 — intervention group
Group type: EXPERIMENTAL
Intervention: Bulimia nervosa-nonpurging subtype (BN-NP)
Number of subjects: 112
Study 24282157 — intervention group
Group type: COMPARATOR
Intervention: Bulimia nervosa-purging subtype (BN-P)
Number of subjects: 112
Study 23033993 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrogen dioxide (NO₂, 0.5 ppm)
Number of subjects: 0
Study 23033993 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated fine particles from Chapel Hill air (PM(2.5)CAPs, 89.5 ± 10.7 µg/m³)
Number of subjects: 0
Study 23033993 — intervention group
Group type: EXPERIMENTAL
Intervention: NO₂ + PM(2.5)CAPs
Number of subjects: 0
Study 23033993 — intervention group
Group type: COMPARATOR
Intervention: Clean air (control)
Number of subjects: 0
Study 20409064 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based patient support system
Number of subjects: 149
Study 20409064 — intervention group
Group type: COMPARATOR
Intervention: Leaflets
Number of subjects: 149
Study 17609300 — intervention group
Group type: EXPERIMENTAL
Intervention: Cortisol withdrawal
Number of subjects: 7
Study 17609300 — intervention group
Group type: COMPARATOR
Intervention: Replacement control
Number of subjects: 7
Study 16136342 — intervention group
Group type: COMPARATOR
Intervention: Exercise and advice
Number of subjects: 41
Study 16136342 — intervention group
Group type: EXPERIMENTAL
Intervention: Activity-focussed physiotherapy
Number of subjects: 41
Study 12412824 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium citrate
Number of subjects: 25
Study 12412824 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium carbonate
Number of subjects: 25
Study 10452208 — intervention group
Group type: EXPERIMENTAL
Intervention: ReliefBand (TENS unit)
Number of subjects: 42
Study 10452208 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 42
Study 10452208 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 42
Study 8569136 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐CaP (supplemented formula with Ca 87 mg/dl, P 43 mg/dl)
Number of subjects: 79
Study 8569136 — intervention group
Group type: COMPARATOR
Intervention: F (non-supplemented formula with Ca 62 mg/dl, P 36 mg/dl)
Number of subjects: 79
Study 8569136 — intervention group
Group type: EXPERIMENTAL
Intervention: F‐CaP
Number of subjects: 79
Study 2121109 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg/day recombinant human growth hormone (rHGH)
Number of subjects: 40
Study 2121109 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 1104042 — intervention group
Group type: EXPERIMENTAL
Intervention: Catgut layer suture alone
Number of subjects: 324
Study 1104042 — intervention group
Group type: EXPERIMENTAL
Intervention: Catgut layer suture with tension sutures
Number of subjects: 324
Study 1104042 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire sutures alone
Number of subjects: 324
Study 1104042 — intervention group
Group type: EXPERIMENTAL
Intervention: Wire sutures
Number of subjects: 324
Study 31238700 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel and aspirin for 90 days
Number of subjects: 4881
Study 31238700 — intervention group
Group type: COMPARATOR
Intervention: Aspirin alone
Number of subjects: 4881
Study 28663124 — intervention group
Group type: EXPERIMENTAL
Intervention: Vortioxetine
Number of subjects: 0
Study 25210141 — intervention group
Group type: EXPERIMENTAL
Intervention: Early BCG vaccination
Number of subjects: 467
Study 25210141 — intervention group
Group type: COMPARATOR
Intervention: Usual postponed BCG
Number of subjects: 467
Study 23414448 — intervention group
Group type: EXPERIMENTAL
Intervention: Foot massage intervention (n=9)
Number of subjects: 19
Study 23414448 — intervention group
Group type: COMPARATOR
Intervention: Silent resting control (n=10)
Number of subjects: 19
Study 21916906 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid 2 g/day
Number of subjects: 11
Study 21916906 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 18355388 — intervention group
Group type: EXPERIMENTAL
Intervention: Omalizumab
Number of subjects: 419
Study 18355388 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 419
Study 17167137 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus bevacizumab
Number of subjects: 878
Study 17167137 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 878
Study 14566832 — intervention group
Group type: EXPERIMENTAL
Intervention: Condom use
Number of subjects: 148
Study 14566832 — intervention group
Group type: COMPARATOR
Intervention: Noncondom use
Number of subjects: 148
Study 10933131 — intervention group
Group type: EXPERIMENTAL
Intervention: R-thalidomide
Number of subjects: 6
Study 10933131 — intervention group
Group type: EXPERIMENTAL
Intervention: S-thalidomide
Number of subjects: 6
Study 10933131 — intervention group
Group type: EXPERIMENTAL
Intervention: R-thalidomide and S-thalidomide
Number of subjects: 6
Study 8743000 — intervention group
Group type: EXPERIMENTAL
Intervention: Perifoveal laser treatment
Number of subjects: 28
Study 1350935 — intervention group
Group type: EXPERIMENTAL
Intervention: roxatidine 150 mg once daily
Number of subjects: 12
Study 1350935 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 12
Study 6424498 — intervention group
Group type: EXPERIMENTAL
Intervention: Alfentanil (10 times the dose of fentanyl)
Number of subjects: 50
Study 6424498 — intervention group
Group type: EXPERIMENTAL
Intervention: Fentanyl
Number of subjects: 50
Study 6424498 — intervention group
Group type: COMPARATOR
Intervention: Alfentanil and Fentanyl
Number of subjects: 50
Study 31183588 — intervention group
Group type: EXPERIMENTAL
Intervention: Muscle resistance training exercise program
Number of subjects: 120
Study 31183588 — intervention group
Group type: COMPARATOR
Intervention: Stretching exercises
Number of subjects: 120
Study 29794793 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional acupuncture
Number of subjects: 40
Study 29794793 — intervention group
Group type: COMPARATOR
Intervention: Sham acupuncture
Number of subjects: 40
Study 27492539 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambrisentan
Number of subjects: 124
Study 24811202 — intervention group
Group type: EXPERIMENTAL
Intervention: MumsQuit
Number of subjects: 200
Study 24811202 — intervention group
Group type: COMPARATOR
Intervention: Control (information-only website)
Number of subjects: 200
Study 22728648 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium sulphate infusion (40 mg/kg for 15 min followed by 10 mg/kg/h during surgery)
Number of subjects: 60
Study 22728648 — intervention group
Group type: COMPARATOR
Intervention: Control group (isotonic saline)
Number of subjects: 60
Study 20639739 — intervention group
Group type: EXPERIMENTAL
Intervention: Etodolac (300 mg) - Paracetamol (500 mg) combination
Number of subjects: 220
Study 20639739 — intervention group
Group type: COMPARATOR
Intervention: Etodolac (300 mg) alone
Number of subjects: 220
Study 16451153 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypothermic CPB (32 degrees C)
Number of subjects: 30
Study 16451153 — intervention group
Group type: COMPARATOR
Intervention: Normothermic CPB (36 degrees C)
Number of subjects: 30
Study 14979681 — intervention group
Group type: EXPERIMENTAL
Intervention: Very-low-calorie diet (VLCD) for nine weeks
Number of subjects: 20
Study 10856145 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (FP) 88 microg twice daily
Number of subjects: 451
Study 10856145 — intervention group
Group type: COMPARATOR
Intervention: Zafirlukast 20 mg twice daily
Number of subjects: 451
Study 9085723 — intervention group
Group type: EXPERIMENTAL
Intervention: Early prevention program facilitated by occupational therapists (approximately 0.5 hours of intervention once every 8 weeks during the infants' first year of life)
Number of subjects: 55
Study 9085723 — intervention group
Group type: COMPARATOR
Intervention: Control group (54 mothers and their infants who did not receive the intervention)
Number of subjects: 55
Study 1311658 — intervention group
Group type: EXPERIMENTAL
Intervention: Amino acid solution starting on post-natal day 2 (Group A)
Number of subjects: 18
Study 1311658 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group B) starting amino acid solution after day 4
Number of subjects: 18
Study 3516000 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular meptazinol (1 mg/kg)
Number of subjects: 100
Study 3516000 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular pethidine (1 mg/kg)
Number of subjects: 100
Study 3516000 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 100
Study 31433479 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-in simple
Number of subjects: 1246
Study 31433479 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-in detailed
Number of subjects: 1246
Study 31433479 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out simple
Number of subjects: 1246
Study 31433479 — intervention group
Group type: EXPERIMENTAL
Intervention: Opt-out detailed
Number of subjects: 1246
Study 31433479 — intervention group
Group type: COMPARATOR
Intervention: Opt-out vs Opt-in interfaces
Number of subjects: 1246
Study 31433479 — intervention group
Group type: COMPARATOR
Intervention: Simple vs Detailed forms
Number of subjects: 1246
Study 30157913 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose ketamine (0.5 mg/kg) intravenously for 40 min during dural mater incision.
Number of subjects: 80
Study 30157913 — intervention group
Group type: COMPARATOR
Intervention: Placebo (normal saline) administered at the same volume and infusion rate during the same time points.
Number of subjects: 80
Study 26946617 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of cervus and cucumis polypeptides
Number of subjects: 96
Study 26946617 — intervention group
Group type: COMPARATOR
Intervention: Physical therapy and rehabilitation exercises (Control)
Number of subjects: 96
Study 25203380 — intervention group
Group type: EXPERIMENTAL
Intervention: Orange juice with polyethylene glycol-ascorbic acid
Number of subjects: 107
Study 25203380 — intervention group
Group type: COMPARATOR
Intervention: Polyethylene glycol-ascorbic acid
Number of subjects: 107
Study 22382341 — intervention group
Group type: EXPERIMENTAL
Intervention: CE-224,535 (500 mg bid)
Number of subjects: 0
Study 22382341 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 19727904 — intervention group
Group type: EXPERIMENTAL
Intervention: 67.5 mmol of bicarbonate daily for 3 months
Number of subjects: 162
Study 19727904 — intervention group
Group type: COMPARATOR
Intervention: No bicarbonate
Number of subjects: 162
Study 17953887 — intervention group
Group type: EXPERIMENTAL
Intervention: Implantation of circulatory assist devices as a permanent alternative to heart transplantation
Number of subjects: 0
Study 17953887 — intervention group
Group type: EXPERIMENTAL
Intervention: New generations of rotator pumps
Number of subjects: 0
Study 16848262 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microl acidified thiourea and 20 microl 30 per cent w/w hydrogen peroxide (Group 5)
Number of subjects: 35
Study 16848262 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microl acidified thiourea and 20 microl one per cent sodium hypochlorite (Group 6)
Number of subjects: 35
Study 16848262 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microl acidified thiourea, 20 microl one per cent sodium hypochlorite and 20 microl 30 per cent w/w hydrogen peroxide (Group 7)
Number of subjects: 35
Study 16848262 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microl 30 per cent w/w hydrogen peroxide (Group 2)
Number of subjects: 35
Study 16848262 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 microl 30 per cent w/w hydrogen peroxide and thermocatalytically activated (Group 3)
Number of subjects: 35
Study 16848262 — intervention group
Group type: COMPARATOR
Intervention: Negative control (Group 1)
Number of subjects: 35
Study 14620212 — intervention group
Group type: EXPERIMENTAL
Intervention: Canine-guided dentures
Number of subjects: 22
Study 14620212 — intervention group
Group type: COMPARATOR
Intervention: Balanced occlusion dentures
Number of subjects: 22
Study 10752972 — intervention group
Group type: EXPERIMENTAL
Intervention: Delavirdine treatment
Number of subjects: 1112
Study 8883526 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol 270 mg I/ml (IOD-270)
Number of subjects: 0
Study 8883526 — intervention group
Group type: EXPERIMENTAL
Intervention: Iodixanol 320 mg I/ml (IOD-320)
Number of subjects: 0
Study 8883526 — intervention group
Group type: COMPARATOR
Intervention: Iohexol 300 mg I/ml (IOH-300)
Number of subjects: 0
Study 1610009 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (0.3 microgram.kg‐1) in group 1 (normal function)
Number of subjects: 115
Study 1610009 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin acetate (0.3 microgram.kg‐1) in group 2 (abnormal function)
Number of subjects: 115
Study 1610009 — intervention group
Group type: COMPARATOR
Intervention: Placebo in group 1 (normal function)
Number of subjects: 115
Study 1610009 — intervention group
Group type: COMPARATOR
Intervention: Placebo in group 2 (abnormal function)
Number of subjects: 115
Study 3984919 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg of ascorbic acid for 1 day followed by 250 mg/day for 2 days
Number of subjects: 25
Study 3984919 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg of ascorbic acid for 1 day followed by 500 mg/day for 2 days
Number of subjects: 25
Study 3984919 — intervention group
Group type: EXPERIMENTAL
Intervention: 90 mg of ascorbic acid for 1 day followed by 1000 mg/day for 2 days
Number of subjects: 25
Study 3984919 — intervention group
Group type: COMPARATOR
Intervention: unsupplemented for 1 day followed by 0 mg ascorbic acid supplement for 2 days
Number of subjects: 25
Study 3984919 — intervention group
Group type: EXPERIMENTAL
Intervention: unsupplemented for 1 day followed by 90 mg ascorbic acid supplement for 2 days
Number of subjects: 25
Study 30894226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral tissue oxygen saturation (crSO2) monitoring combined with defined treatment guidelines
Number of subjects: 0
Study 30894226 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring and treatment as usual
Number of subjects: 0
Study 30894226 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebral tissue oxygen saturation (crSO2) monitoring
Number of subjects: 0
Study 30894226 — intervention group
Group type: EXPERIMENTAL
Intervention: Defined treatment guidelines
Number of subjects: 0
Study 30894226 — intervention group
Group type: EXPERIMENTAL
Intervention: Mortality or cerebral injury (or both) defined as any intra-ventricular bleeding or cystic periventricular leukomalacia (or both)
Number of subjects: 0
Study 30894226 — intervention group
Group type: EXPERIMENTAL
Intervention: Neonatal morbidities
Number of subjects: 0
Study 27548784 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable resistance (WR) of 3% body mass (BM) affixed to the anterior surface of the lower limbs
Number of subjects: 19
Study 27548784 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable resistance (WR) of 3% body mass (BM) affixed to the posterior surface of the lower limbs
Number of subjects: 19
Study 27548784 — intervention group
Group type: EXPERIMENTAL
Intervention: Wearable resistance (WR) of 3% body mass (BM)
Number of subjects: 19
Study 27548784 — intervention group
Group type: COMPARATOR
Intervention: No resistance (unloaded sprints)
Number of subjects: 19
Study 25539986 — intervention group
Group type: EXPERIMENTAL
Intervention: Microinjections of HA salts of biotechnological origin, once weekly for 4 weeks and then once monthly for 4 months (group A) or 9 months (group B)
Number of subjects: 22
Study 25539986 — intervention group
Group type: EXPERIMENTAL
Intervention: Microinjections of HA salts of biotechnological origin, after an additional 4 months of monthly injections
Number of subjects: 22
Study 25539986 — intervention group
Group type: EXPERIMENTAL
Intervention: Microinjections of HA salts of biotechnological origin, in patients from group B that completed 10 months of treatment
Number of subjects: 22
Study 25539986 — intervention group
Group type: COMPARATOR
Intervention: Saline solution injected into the dorsum of the other hand (control)
Number of subjects: 22
Study 23451990 — intervention group
Group type: EXPERIMENTAL
Intervention: nHA of particle size 10 to 100 nm
Number of subjects: 60
Study 23451990 — intervention group
Group type: EXPERIMENTAL
Intervention: nHA with 24% EDTA treatment
Number of subjects: 60
Study 23451990 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite graft of nHA and β‐TCP (particle size 63 to 150 nm)
Number of subjects: 60
Study 23451990 — intervention group
Group type: EXPERIMENTAL
Intervention: Composite graft of nHA and β‐TCP with 24% EDTA treatment
Number of subjects: 60
Study 21330457 — intervention group
Group type: EXPERIMENTAL
Intervention: SNP rs11046966 from the SOX5 gene
Number of subjects: 810
Study 21330457 — intervention group
Group type: EXPERIMENTAL
Intervention: Sox5(‐/‐) mice
Number of subjects: 810
Study 21330457 — intervention group
Group type: COMPARATOR
Intervention: Control group (424 control smokers)
Number of subjects: 810
Study 19057413 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (2.5-20.0 mg/day)
Number of subjects: 107
Study 19057413 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 107
Study 17293605 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching intervention (small group discussion)
Number of subjects: 15
Study 17293605 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching intervention (structured feedback on student-patient interview)
Number of subjects: 15
Study 17293605 — intervention group
Group type: EXPERIMENTAL
Intervention: Teaching intervention (general teaching methods)
Number of subjects: 15
Study 15488052 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol anaesthesia
Number of subjects: 18
Study 15488052 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane anaesthesia
Number of subjects: 18
Study 11238495 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-677 (25 mg) plus alendronate (10 mg)
Number of subjects: 292
Study 11238495 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-677 (25 mg)
Number of subjects: 292
Study 11238495 — intervention group
Group type: EXPERIMENTAL
Intervention: MK-677 plus alendronate
Number of subjects: 292
Study 9587118 — intervention group
Group type: EXPERIMENTAL
Intervention: Fine-needle aspiration cytology (FNAC) and 14-gauge core needle biopsy (CB)
Number of subjects: 823
Study 9587118 — intervention group
Group type: COMPARATOR
Intervention: Open surgical biopsy (OSB)
Number of subjects: 823
Study 9587118 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph node metastasis rate
Number of subjects: 823
Study 7822672 — intervention group
Group type: EXPERIMENTAL
Intervention: Thin disposable soft contact lenses (0.07 mm thickness)
Number of subjects: 10
Study 7822672 — intervention group
Group type: COMPARATOR
Intervention: Standard disposable soft contact lenses (0.105 mm thickness)
Number of subjects: 10
Study 2977527 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex (3.6 mg depot administered every four weeks for 3 times)
Number of subjects: 82
Study 2977527 — intervention group
Group type: COMPARATOR
Intervention: Control group (300 mg diethylstilbestrol diphosphate orally daily for 12 weeks or orchidectomy)
Number of subjects: 82
Study 2977527 — intervention group
Group type: EXPERIMENTAL
Intervention: Zoladex
Number of subjects: 82
Study 2977527 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 82
Study 2977527 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 82
Study 30688407 — intervention group
Group type: EXPERIMENTAL
Intervention: Corneal epithelial stem cells cultured on amniotic membrane (AM) with systemic immunosuppression
Number of subjects: 16
Study 30688407 — intervention group
Group type: COMPARATOR
Intervention: Control group: Amniotic membrane (AM) only with systemic immunosuppression
Number of subjects: 16
Study 29553442 — intervention group
Group type: EXPERIMENTAL
Intervention: Text-message reminder intervention
Number of subjects: 1000
Study 29553442 — intervention group
Group type: COMPARATOR
Intervention: No text-message reminder (baseline)
Number of subjects: 1000
Study 26976446 — intervention group
Group type: EXPERIMENTAL
Intervention: Enamel matrix derivative (EMD)
Number of subjects: 12
Study 26976446 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated cells)
Number of subjects: 12
Study 26976446 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD
Number of subjects: 12
Study 26976446 — intervention group
Group type: COMPARATOR
Intervention: Control (clinical study)
Number of subjects: 12
Study 25098569 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile phone intervention including SMS coaching, USSD questionnaire, and family planning information via SMS and Mxit.
Number of subjects: 234
Study 22922775 — intervention group
Group type: EXPERIMENTAL
Intervention: Prednisone (PRED) 40 mg/m²/day for 28 days
Number of subjects: 29
Study 22922775 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX) 6 mg/m²/day for 28 days
Number of subjects: 29
Study 22922775 — intervention group
Group type: COMPARATOR
Intervention: Control group (16 children without ALL)
Number of subjects: 29
Study 20061337 — intervention group
Group type: EXPERIMENTAL
Intervention: Closed circuits without cardiotomy suction (closed group, n=15)
Number of subjects: 30
Study 20061337 — intervention group
Group type: COMPARATOR
Intervention: Open circuits with open reservoirs and cardiotomy suction (open group, n=15)
Number of subjects: 30
Study 20061337 — intervention group
Group type: COMPARATOR
Intervention: Open circuits (open group)
Number of subjects: 30
Study 18685360 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin-based combination chemotherapy
Number of subjects: 0
Study 18685360 — intervention group
Group type: COMPARATOR
Intervention: Newer regimens (not specified)
Number of subjects: 0
Study 18685360 — intervention group
Group type: COMPARATOR
Intervention: Addition of a third agent to doublet combinations
Number of subjects: 0
Study 18685360 — intervention group
Group type: COMPARATOR
Intervention: New drugs (pemetrexed and vinflunine)
Number of subjects: 0